Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Irinotecan liposome + capecitabine + bevacizumab in second-line metastatic colorectal cancer
ChiCTR2400092345Phase 2Not yet recruiting
- Sponsor
- Affiliated Cancer Hospital of Nanjing Medical University
- Start
- Nov 2024
- Modality
- Small Molecules, Liposomes → Lipid-based Nanoparticles → Nanoparticles → Drug Delivery Systems
- Countries
- 1
01
Overview
Phase 2, open-label trial of irinotecan liposome in metastatic colorectal adenocarcinoma (mCRC) (2 arms), sponsored by Affiliated Cancer Hospital of Nanjing Medical University. Primary endpoint: objective response rate. Planned start Nov 2024; status: not yet recruiting.
02
Drugs
irinotecan liposome
03
Conditions
metastatic colorectal adenocarcinoma (mCRC)
Beyond the preview
Go deeper on ChiCTR2400092345.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2400092345.